Cytokinetics

Cytokinetics LT Debt/Equity

The Long-Term Debt to Equity Ratio of Cytokinetics (CYTK) as of Nov 20, 2026 is -1.69. In the previous year, Long-Term Debt to Equity Ratio was -4.77 — a change of -64.52% (higher).

LT Debt/Equity

-1.69

YoY

-64.52%

Last updated:

Long-Term Debt to Equity Ratio of Cytokinetics is 2025 -1.69 . Long-Term Debt to Equity Ratio of Cytokinetics was 2024 -4.77 . It decreases by -64.52% higher compared to the previous year.

The Cytokinetics LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
1.53 USD
Jan 1, 2019
-4.12 USD
Jan 1, 2020
0.41 USD
Jan 1, 2021
0.19 USD
Jan 1, 2022
-0.59 USD
Jan 1, 2023
-1.57 USD
Jan 1, 2024
-4.77 USD
Jan 1, 2025
-1.69 USD
The Cytokinetics LT Debt/Equity history
YEARLT Debt/EquityYoY
-1.69-64.52%
-4.77+203.34%
-1.57+165.85%
-0.59-404.46%
0.19-52.34%
0.41-109.89%
-4.12-368.37%
1.53+430.56%
0.29-0.30%
0.29+35.96%
0.21—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytokinetics Stock analysis

What does Cytokinetics do? Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytokinetics stock

Long-Term Debt to Equity Ratio of Cytokinetics is -1.69 in 2025.

Long-Term Debt to Equity Ratio of Cytokinetics changed from -4.77 to -1.69, representing a -64.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Cytokinetics since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Cytokinetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cytokinetics

All Key Metrics — Cytokinetics